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Abstract
Introduction: The opioid epidemic persists in the United States. The use of opioid medications is often assessed by claims data but
potentially underestimated.
Objectives: We evaluated the temporal trend in the use of opioid and nonopioid pain medications from a national survey.
Methods: Using data from the 2001 to 2018 National Health and Nutrition Examination Survey (NHANES), we examined the current
use of prescription analgesics in the past 30 days among 50,201 respondents aged 20 years or older. Joinpoint regressions were
used to test statistically meaningful trends of opioid vs nonopioid analgesics.
Results: The mean percentage of people who had pain medications in the past 30 days was 6.4% (5.3%-7.1%) for opioid and
11.3% (9.0%-14.8%) for nonopioid analgesics. The availability of opioid and nonopioid prescriptions at home has remained stable,
except for the slight decline of opioids among cancer-free patients in 2005 to 2018. The most frequently used opioid analgesic
medications included hydrocodone/acetaminophen, tramadol, and hydrocodone.
Conclusion: We uniquely measured the proportion of people who had opioid and nonopioid pain medications at home in the United
States and supplemented the previous knowledge of prescription rates mainly obtained from claims data.
Keywords: Prescription pain reliever, Analgesics, Opioid

1. Introduction
The opioid crisis is a pervasive public health threat in the United
States.6 The existing analyses of opioid pain medications mainly
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rely on claims data.3,7,9 However, the claims data failed to capture
the nonmedical use of prescription opioids, given that approximately half of those who misused prescription painkillers obtained
these medications from a friend or relative.10 The National Health
and Nutrition Examination Survey (NHANES) may serve as an
appropriate data source to illustrate the secular trend of patients’
actual use of opioid and nonopioid analgesics at home.

2. Material and methods
The NHANES is a program under the Centers for Disease Control
and Prevention (CDC) designed to collect nationally representative
data for noninstitutionalized civilians in the US population and
assess the health and nutritional status through interviews, physical
examinations, and laboratory analysis of biological specimens.16
The NHANES survey provided the weights and strata for
oversampling, complex sampling methods, and nonresponse,
which we used for all analyses.15 We extracted a total of 9 cycle
data from the NHANES from 2001/02 to 2017/18, a populationbased home interview survey among nationally representative
civilian, noninstitutionalized adults aged 20 years or older in the
United States. The most recent 2019 to 2020 cycle data were not
complete because of the coronavirus disease 2019 pandemic and
therefore excluded. In short, participants were asked whether they
had taken any medicines in the past 30 days for which they needed
a prescription. Those responding yes were asked to show the
containers of all medications; when unavailable, the participants
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verbally reported the medication name. Medications were coded
using the Multum Lexicon Therapeutic Classification Scheme.15
Opioids (methadone, buprenorphine, and naloxone) often used in
the treatment of opioid use disorder were excluded from opioid
pain medications. Pain medication was classified for on-label12 use
as analgesics.5,15
We first estimated each 2-year survey cycle’s prevalence rate
for opioid and nonopioid pain medications (drug codes shown in
Supplementary Table 1, available at http://links.lww.com/PR9/
A161),13 respectively, in total, cancer patients/survivors, and
cancer-free patients. We classified participants as cancer
patients/survivors if they answered yes to “Ever told you had
cancer or malignancy?” Second, we quantified the average biannual percentage change (b-APC) by the joinpoint regression
(Joinpoint Statistical Software, version 4.2.0.2)10 to characterize
statistically meaningful trends with a significance level of 0.05 in
rates over time. We reported only significant b-APC in this report,
which indicated a statistically significant change in trend (namely
the increasing or decreasing slope) before and after a time point.
Finally, we identified the top 10 most prevalent prescription
analgesics in each survey wave (Supplementary Table 2, available
at http://links.lww.com/PR9/A161). Our study was deemed
exempt from ethics review due to the use of publicly accessible
nonidentifiable data. We adjusted the sampling weights in all
analyses to account for the complex survey design and
nonresponse bias.

3. Results
Among 50,201 respondents from the 9 cycle surveys, 11.3%
reported the current use of nonopioid medications, whereas
6.4% reported having opioid pain medications at home in the past
30 days. From 2001/02 to 2017/18, the prevalence rates of
opioid and nonopioid prescription use (Fig. 1) remained at stable
levels of 5.3% to 7.1% and 9.0% to 14.8%, respectively. We
observed only a statistically meaningful decline of opioid
analgesics among individuals without a history of cancer
(accounting for 90.5% of the total sample), diminishing from
6.3% in 2005/2006 to 5.1% in 2017/2018 at a bi-annual decline
rate of 2.02% (b-APC 5 22.02, P , 0.05).
We identified 2 medication patterns from 2001 to 2018. First, of
the top 10 most prevalent analgesic medications in each cycle, at
least 2 were opioid pain medications in cancer patients and
cancer-free individuals. The most prevalent analgesic medications
included hydrocodone/acetaminophen (equivalent to morphine
opioid), gabapentin, ibuprofen, naproxen, tramadol (weaker than
morphine), aspirin, celecoxib, venlafaxine, meloxicam, and hydrocodone (equivalent to morphine) (Supplementary Table 2, available
at http://links.lww.com/PR9/A161). Hydrocodone/acetaminophen
ranked the most often used analgesic from 2005 to 2012 but lost its
top ranking in 2013/2014 (Supplementary Table 2, available at http://
links.lww.com/PR9/A161). The opioid tramadol has become a
popular drug since 2005. Ibuprofen and naproxen continued to be
the most prevalent nonsteroidal anti-inflammatory drugs (NSAIDs)
(Supplementary Table 2, available at http://links.lww.com/PR9/
A161). We seemed to observe a bump in gabapentin prescriptions,
a drug commonly used to treat neuropathic pain (Supplementary
Table 2, available at http://links.lww.com/PR9/A161).

4. Discussion
We assessed the use of opioid vs nonopioid analgesics in a large
nationally representative US sample over time. Findings indicate that
the use of opioid and nonopioid analgesics held relatively stable from
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2001 to 2018, except for a slight decline of opioid pain medications in
2005 to 2018 among individuals without a history of cancer. We
measured the proportion of people who self-reported using opioid
and nonopioid prescriptions from an in-home survey to supplement
the literature estimates mainly from claims data. Retail prescription
data from Quintiles and IMS Health Inc. indicated that opioid
prescribing peaked in 2010 (81.2 prescriptions per 100 persons)
and decreased annually until 2015.9 The national opioid dispensing
rate map3 found that the total number of opioid prescriptions peaked
in 2012 after a steady increase since 2006. In another study of
Medicare beneficiaries, researchers7 found a significant decline (21%
among oncologists and 23% among other doctors) of opioid
prescriptions from 2013 to 2017. We uniquely studied the proportion
of opioid and nonopioid prescriptions at home and observed a stable
trend of opioid and nonopioid prescriptions among cancer patients.
The public health implications of our findings are significant, especially
considering that approximately 20% of individuals who misuse
prescription pain relievers obtained these medications from healthcare providers.11 Together with the existing literature, our analysis
results indicated that prescription opioids were often used to treat
pain at home, but fewer cancer-free patients have had opioids since
2005. Even among individuals without a history of cancer, we found
that of the top 10 most prevalent analgesic medications, 3 were opioid
medications. Acetaminophen/hydrocodone (equivalent to morphine)
was the most prevalent analgesic drug. Unlike other countries,4 the
United States puts minimal constraints on the medical use of
hydrocodone, a long-acting and highly addictive opioid medication.
Hydrocodone was once a Schedule III drug in the United States,
rather than the more restrictive Schedule II drug. People could obtain
a prescription of Schedule III drug refilled at the pharmacy without
seeing a doctor.14 To reduce misuse, the Drug Enforcement
Administration (DEA) changed the schedule of hydrocodone
combination products from Schedule III to Schedule II (indicating
substance has a higher potential for abuse). Our results show
changes coincided with the implementation of this policy since
2014.14 The historically safer opioid tramadol has increased since
2007. Recent research reported that tramadol is more likely than
other opioids to result in prolonged use.16 However, the Drug
Enforcement Administration (DEA) still treats tramadol as a Schedule
IV controlled substance (indicating a lower potential for abuse than
substances in Schedules I–III). Given its increasing popularity (from the
seventh most common analgesic in 2003/2004 to the fifth in 2017/
18), the Schedule IV classification of tramadol should be reassessed.
In an earlier survey conducted in 1997, ibuprofen-based drugs
were the most frequently used nonopioid drug.17 Our analysis
showed that gabapentin was favored beyond ibuprofen during
2007 to 2016. However, gabapentin was approved by the FDA
under the classification of anticonvulsants and only had on-label
use for pain relief for postherpetic neuralgia.1 There was no strong
evidence that the wide use of gabapentin was only for pain relief
purposes. We might say that ibuprofen remained to be the most
persuasive nonopioid pain medication. As of July 2018,
Tennessee, West Virginia, and Kentucky have classified gabapentin as a Schedule V medication in the controlled substance
schedule. More states require the report of gabapentin to
prescription drug monitoring programs. The current widespread
use of gabapentin that we identified was quite alarming.
There are several noteworthy limitations. NHANES relied on
respondents’ self-report of medication use and lacked an
assessment of the amount and duration of the medication use.
While we captured self-reported opioid medication use, we were
uncertain for which medical purpose these medications were
taken and whether they obtained the drug from multiple sources
(for instance, from their friends or family). Each NHANES survey
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Figure 1. (A) Temporal trends of opioid analgesic use in the United States in all cancer patients and noncancer individuals, 2001 to 2018. (B) Temporal trends of
nonopioid analgesic use in the United States in all cancer patients and noncancer individuals, 2001 to 2018.

intentionally oversampled certain subgroups of population to
increase the national representativeness but may overestimate
some populations (such as undersampling of other than nonHispanic Black and Mexican American minority groups and
intentionally overweighting non-White populations).8 Similarly,
the focus on persons in dwelling units excluded the homeless,
which then underestimated opioid use.

5. Conclusions
In summary, we found that approximately 6% and 11% of people
had opioid and nonopioid analgesics at home in the past 30 days.
The availability of opioid and nonopioid drugs remained stable,
except for the slight decline of opioids among cancer-free patients

since 2005. The most frequently used opioid analgesic medications included hydrocodone/acetaminophen, tramadol, and
hydrocodone. Public health policymakers should supplement
survey data with claims data to improve the understanding of the
trends of opioid misuse to design effective interventional programs.
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